Cargando…

The lower airways microbiota and antimicrobial peptides indicate dysbiosis in sarcoidosis

BACKGROUND: The role of the pulmonary microbiome in sarcoidosis is unknown. The objectives of this study were the following: (1) examine whether the pulmonary fungal and bacterial microbiota differed in patients with sarcoidosis compared with controls; (2) examine whether there was an association be...

Descripción completa

Detalles Bibliográficos
Autores principales: Knudsen, Kristel S., Lehmann, Sverre, Nielsen, Rune, Tangedal, Solveig, Paytuvi-Gallart, Andreu, Sanseverino, Walter, Martinsen, Einar M. H., Hiemstra, Pieter S., Eagan, Tomas M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9580159/
https://www.ncbi.nlm.nih.gov/pubmed/36258251
http://dx.doi.org/10.1186/s40168-022-01362-4
_version_ 1784812332992430080
author Knudsen, Kristel S.
Lehmann, Sverre
Nielsen, Rune
Tangedal, Solveig
Paytuvi-Gallart, Andreu
Sanseverino, Walter
Martinsen, Einar M. H.
Hiemstra, Pieter S.
Eagan, Tomas M.
author_facet Knudsen, Kristel S.
Lehmann, Sverre
Nielsen, Rune
Tangedal, Solveig
Paytuvi-Gallart, Andreu
Sanseverino, Walter
Martinsen, Einar M. H.
Hiemstra, Pieter S.
Eagan, Tomas M.
author_sort Knudsen, Kristel S.
collection PubMed
description BACKGROUND: The role of the pulmonary microbiome in sarcoidosis is unknown. The objectives of this study were the following: (1) examine whether the pulmonary fungal and bacterial microbiota differed in patients with sarcoidosis compared with controls; (2) examine whether there was an association between the microbiota and levels of the antimicrobial peptides (AMPs) in protected bronchoalveolar lavage (PBAL). METHODS: Thirty-five sarcoidosis patients and 35 healthy controls underwent bronchoscopy and were sampled with oral wash (OW), protected BAL (PBAL), and left protected sterile brushes (LPSB). The fungal ITS1 region and the V3V4 region of the bacterial 16S rRNA gene were sequenced. Bioinformatic analyses were performed with QIIME 2. The AMPs secretory leucocyte protease inhibitor (SLPI) and human beta defensins 1 and 2 (hBD-1 and hBD-2), were measured in PBAL by enzyme-linked immunosorbent assay (ELISA). RESULTS: Aspergillus dominated the PBAL samples in sarcoidosis. Differences in bacterial taxonomy were minor. There was no significant difference in fungal alpha diversity between sarcoidosis and controls, but the bacterial alpha diversity in sarcoidosis was significantly lower in OW (p = 0.047) and PBAL (p = 0.03) compared with controls. The beta diversity for sarcoidosis compared with controls differed for both fungi and bacteria. AMP levels were significantly lower in sarcoidosis compared to controls (SLPI and hBD-1: p < 0.01). No significant correlations were found between alpha diversity and AMPs. CONCLUSIONS: The pulmonary fungal and bacterial microbiota in sarcoidosis differed from in controls. Lower antimicrobial peptides levels were seen in sarcoidosis, indicating an interaction between the microbiota and the innate immune system. Whether this dysbiosis represents a pathogenic mechanism in sarcoidosis needs to be confirmed in experimental studies. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s40168-022-01362-4.
format Online
Article
Text
id pubmed-9580159
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-95801592022-10-20 The lower airways microbiota and antimicrobial peptides indicate dysbiosis in sarcoidosis Knudsen, Kristel S. Lehmann, Sverre Nielsen, Rune Tangedal, Solveig Paytuvi-Gallart, Andreu Sanseverino, Walter Martinsen, Einar M. H. Hiemstra, Pieter S. Eagan, Tomas M. Microbiome Research BACKGROUND: The role of the pulmonary microbiome in sarcoidosis is unknown. The objectives of this study were the following: (1) examine whether the pulmonary fungal and bacterial microbiota differed in patients with sarcoidosis compared with controls; (2) examine whether there was an association between the microbiota and levels of the antimicrobial peptides (AMPs) in protected bronchoalveolar lavage (PBAL). METHODS: Thirty-five sarcoidosis patients and 35 healthy controls underwent bronchoscopy and were sampled with oral wash (OW), protected BAL (PBAL), and left protected sterile brushes (LPSB). The fungal ITS1 region and the V3V4 region of the bacterial 16S rRNA gene were sequenced. Bioinformatic analyses were performed with QIIME 2. The AMPs secretory leucocyte protease inhibitor (SLPI) and human beta defensins 1 and 2 (hBD-1 and hBD-2), were measured in PBAL by enzyme-linked immunosorbent assay (ELISA). RESULTS: Aspergillus dominated the PBAL samples in sarcoidosis. Differences in bacterial taxonomy were minor. There was no significant difference in fungal alpha diversity between sarcoidosis and controls, but the bacterial alpha diversity in sarcoidosis was significantly lower in OW (p = 0.047) and PBAL (p = 0.03) compared with controls. The beta diversity for sarcoidosis compared with controls differed for both fungi and bacteria. AMP levels were significantly lower in sarcoidosis compared to controls (SLPI and hBD-1: p < 0.01). No significant correlations were found between alpha diversity and AMPs. CONCLUSIONS: The pulmonary fungal and bacterial microbiota in sarcoidosis differed from in controls. Lower antimicrobial peptides levels were seen in sarcoidosis, indicating an interaction between the microbiota and the innate immune system. Whether this dysbiosis represents a pathogenic mechanism in sarcoidosis needs to be confirmed in experimental studies. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s40168-022-01362-4. BioMed Central 2022-10-19 /pmc/articles/PMC9580159/ /pubmed/36258251 http://dx.doi.org/10.1186/s40168-022-01362-4 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Knudsen, Kristel S.
Lehmann, Sverre
Nielsen, Rune
Tangedal, Solveig
Paytuvi-Gallart, Andreu
Sanseverino, Walter
Martinsen, Einar M. H.
Hiemstra, Pieter S.
Eagan, Tomas M.
The lower airways microbiota and antimicrobial peptides indicate dysbiosis in sarcoidosis
title The lower airways microbiota and antimicrobial peptides indicate dysbiosis in sarcoidosis
title_full The lower airways microbiota and antimicrobial peptides indicate dysbiosis in sarcoidosis
title_fullStr The lower airways microbiota and antimicrobial peptides indicate dysbiosis in sarcoidosis
title_full_unstemmed The lower airways microbiota and antimicrobial peptides indicate dysbiosis in sarcoidosis
title_short The lower airways microbiota and antimicrobial peptides indicate dysbiosis in sarcoidosis
title_sort lower airways microbiota and antimicrobial peptides indicate dysbiosis in sarcoidosis
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9580159/
https://www.ncbi.nlm.nih.gov/pubmed/36258251
http://dx.doi.org/10.1186/s40168-022-01362-4
work_keys_str_mv AT knudsenkristels thelowerairwaysmicrobiotaandantimicrobialpeptidesindicatedysbiosisinsarcoidosis
AT lehmannsverre thelowerairwaysmicrobiotaandantimicrobialpeptidesindicatedysbiosisinsarcoidosis
AT nielsenrune thelowerairwaysmicrobiotaandantimicrobialpeptidesindicatedysbiosisinsarcoidosis
AT tangedalsolveig thelowerairwaysmicrobiotaandantimicrobialpeptidesindicatedysbiosisinsarcoidosis
AT paytuvigallartandreu thelowerairwaysmicrobiotaandantimicrobialpeptidesindicatedysbiosisinsarcoidosis
AT sanseverinowalter thelowerairwaysmicrobiotaandantimicrobialpeptidesindicatedysbiosisinsarcoidosis
AT martinseneinarmh thelowerairwaysmicrobiotaandantimicrobialpeptidesindicatedysbiosisinsarcoidosis
AT hiemstrapieters thelowerairwaysmicrobiotaandantimicrobialpeptidesindicatedysbiosisinsarcoidosis
AT eagantomasm thelowerairwaysmicrobiotaandantimicrobialpeptidesindicatedysbiosisinsarcoidosis
AT knudsenkristels lowerairwaysmicrobiotaandantimicrobialpeptidesindicatedysbiosisinsarcoidosis
AT lehmannsverre lowerairwaysmicrobiotaandantimicrobialpeptidesindicatedysbiosisinsarcoidosis
AT nielsenrune lowerairwaysmicrobiotaandantimicrobialpeptidesindicatedysbiosisinsarcoidosis
AT tangedalsolveig lowerairwaysmicrobiotaandantimicrobialpeptidesindicatedysbiosisinsarcoidosis
AT paytuvigallartandreu lowerairwaysmicrobiotaandantimicrobialpeptidesindicatedysbiosisinsarcoidosis
AT sanseverinowalter lowerairwaysmicrobiotaandantimicrobialpeptidesindicatedysbiosisinsarcoidosis
AT martinseneinarmh lowerairwaysmicrobiotaandantimicrobialpeptidesindicatedysbiosisinsarcoidosis
AT hiemstrapieters lowerairwaysmicrobiotaandantimicrobialpeptidesindicatedysbiosisinsarcoidosis
AT eagantomasm lowerairwaysmicrobiotaandantimicrobialpeptidesindicatedysbiosisinsarcoidosis